Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States.
The last earnings update was 32 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Aptevo Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Aptevo Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Aptevo Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Aptevo Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Aptevo Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Aptevo Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Aptevo Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Aptevo Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Aptevo Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 2.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Marvin L. White has been the Chief Executive Officer and President at Aptevo Therapeutics Inc. since August 1, 2016. Mr. White has been the President and Chief Executive Officer at The MLW Advisory Group, LLC since April 2014. Mr. White served as Chief Financial Officer and System Vice President at St. Vincent Hospital and Health Care Center, Inc from 2008 to March 2014. He served as Chief Financial Officer at Eli Lilly & Company's Lilly USA, LLC. He served leadership positions at Lilly in Corporate Finance and Investment Banking in the Corporate Strategy Group. He served as the Pharmaceutical Company's Assistant Treasurer. He served as an Executive Director of Eli Lilly & Company's LillyUSA and Lilly pharmaceutical company. Prior to his career in health care, He served with General Motors in Illinois and Hewlett Packard in Atlanta, where he served various supervisory and financial assignments. In 1993, he joined Motorola's Cordless Operation as an Operations Controller and Senior Operations Controller for the Japan Cellular Division since 1995. He moved to Singapore in 1997 as the South Asia Divisional Controller for Motorola's Cellular Sector and served as its Latin America Divisional Controller for the Cellular sector. He served as Chairman of St. Vincent Indianapolis Hospital Board of Directors. He has been a Trustee at HealthLease Properties Real Estate Investment Trust since December 4, 2013. He has been a Director of OneAmerica Financial Insurance Partners, Inc. since September 2014. He serves as a Director of Ryla, Inc. He serves on the Boards of Marian University, Advantage Health Solutions, Inc. Mr. White served as an Independent Director of CoLucid Pharmaceuticals, Inc. since July 13, 2015 until March 1, 2017. He serves as an Independent Director of WP GLIMCHER Inc. from May 7, 2014. He served as a Director of Emergent BioSolutions, Inc. since June 2010 until May 26, 2016. He served as a Director of Lilly USA, LLC. He is active with the Center for Leadership Development, Saving Orphans through Healthcare and Outreach (SOHO) and with the United Way. He has been a Director at Aptevo Therapeutics Inc. since August 1, 2016. He served as a Member of the Arts Council of Indianapolis and the Lynxx Capital Corporation Investment Committee. Mr. White received Master's degree in Business Administration in Finance from Indiana University in 1989 and a Bachelor's degree in Accounting from Wilberforce University in 1984.
Marvin's compensation has increased whilst company is loss making.
Marvin's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Aptevo Therapeutics management team is about average.
Senior VP of Clinical Development & Medical Affairs and Chief Medical Officer
Senior VP of Operations & Chief Manufacturing Officer
Senior VP & Chief Scientific Officer
Senior Director of Investor Relations & Corporate Communications
Senior VP of Corporate Affairs & General Counsel
Senior VP of Commercial Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Aptevo Therapeutics board of directors is less than 3 years, this suggests a new board.
Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.